Crenolanib
Overview[edit | edit source]
Crenolanib is a small molecule tyrosine kinase inhibitor that targets the platelet-derived growth factor receptor (PDGFR) and the FMS-like tyrosine kinase 3 (FLT3). It is primarily investigated for its potential use in treating various types of cancer, including acute myeloid leukemia (AML) and gastrointestinal stromal tumors (GISTs).
Mechanism of Action[edit | edit source]
Crenolanib functions by inhibiting the activity of PDGFR and FLT3, which are often overexpressed or mutated in certain cancers. By blocking these receptors, crenolanib can interfere with the signaling pathways that promote cancer cell proliferation and survival.
Clinical Applications[edit | edit source]
Acute Myeloid Leukemia[edit | edit source]
In acute myeloid leukemia, mutations in the FLT3 gene are common and are associated with poor prognosis. Crenolanib has shown promise in targeting these mutations, particularly the FLT3-ITD and FLT3-D835 mutations, which are resistant to other treatments.
Gastrointestinal Stromal Tumors[edit | edit source]
Crenolanib is also being studied for its efficacy in treating gastrointestinal stromal tumors, especially those that are resistant to other tyrosine kinase inhibitors like imatinib and sunitinib.
Pharmacokinetics[edit | edit source]
Crenolanib is administered orally and has a favorable pharmacokinetic profile, allowing it to be used in combination with other chemotherapeutic agents. Its ability to penetrate the central nervous system makes it a candidate for treating cancers with central nervous system involvement.
Side Effects[edit | edit source]
Common side effects of crenolanib include nausea, diarrhea, fatigue, and liver enzyme abnormalities. As with other tyrosine kinase inhibitors, careful monitoring of patients is necessary to manage these adverse effects.
Research and Development[edit | edit source]
Crenolanib is currently undergoing various clinical trials to evaluate its safety and efficacy in different cancer types. Ongoing research aims to optimize its use in combination therapies and to identify biomarkers that predict response to treatment.
Related Pages[edit | edit source]
- Tyrosine kinase inhibitor
- Acute myeloid leukemia
- Gastrointestinal stromal tumor
- Platelet-derived growth factor receptor
- FMS-like tyrosine kinase 3
Gallery[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
